chitay-knigi.com » Медицина » Неалкогольная жировая болезнь печени - Е. Вовк

Шрифт:

-
+

Интервал:

-
+

Закладка:

Сделать
1 ... 10 11 12 13 14 15 16 17 18 19
Перейти на страницу:

60. Jesch E.D., Carr T.P. Food Ingredients That Inhibit Cholesterol Absorption. Preventive Nutrition and Food Science. 2017;22(2):67–80. doi:10.3746/pnf.2017.22.2.67.

61. Lefebvre P., Cariou B., Lien F. et al. Role of bile acids and bile acid receptors in metabolic regulation. Physiol Rev. 2009 Jan;89(l):147-91. doi: 10.1152/physrev.00010.2008.

62. Watanabe M., Houten S.M., Mataki C. et al. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature. 2006 Jan 26;439(7075):484-9.

63. Willett W.C., Sacks F., Trichopoulou A.,et al. Mediterranean diet pyramid: a cultural model for healthy eating // Am J Clin Nutr. 1995 Jun;61(6 Suppl):1402S-1406S.

64. WHO/FAO (2003) Diet nutrition and the prevention of chronic diseases. Geneva, Switzerland. Available at www.who.int.

65. Hu F.B., Willett W.C. (2002) Optimal diets for prevention of coronary heart disease. JAMA. 2002 Nov 27; 288(20):2569-78. Review.

66. Estruch R., Ros E., Salas-Salvadô J. et al. PREDIMED Study Investigators. Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med. 2013 Apr 4; 368(14):1279-90.

67. Gunge V.B., Andersen I., Куш C., et al. Adherence to a healthy Nordic food index and risk of myocardial infarction in middle-aged Danes: the diet, cancer and health cohort study. Eur J Clin Nutr. 2017 May;71(5):652–658. doi: 10.1038/ ejcn.2017.1. Epub 2017 Mar 1.

68. Sofi F., Casini A. Mediterranean diet and nonalcoholic fatty liver disease: New therapeutic option around the corner? World Journal of Gastroenterology: WJG. 2014;20 (23):7339–7346. doi:10.3748/wjg.v20.i23.7339.

69. Eckard C., Cole R., Lockwood J., et al. Prospective histopathologic evaluation of lifestyle modification in nonalcoholic fatty liver disease: a randomized trial. Therapeutic Advances in Gastroenterology. 2013;6(4):249–259. doi:10.1177/ 1756283X13484078.

70. Tzima N., Pitsavos C., Panagiotakos D.B. et al. Adherence to the Mediterranean diet moderates the association of aminotransferases with the prevalence of the metabolic syndrome; the ATTICA study. Nutr Metab (bond). 2009 Jul 30; 6():30.

71. Martinez-Gonzalez M.A., de la Fuente-Arrillaga C., Nunez-Cordoba J.M. et al. Adherence to Mediterranean diet and risk of developing diabetes: prospective cohort study. BMJ. 2008 Jun 14; 336(7657):1348-51.

72. Ryan M.C., Itsiopoulos C., Thodis T. et al. The Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease. J Hepatol. 2013 Jul;59(l):138-43. doi: 10.1016/j. jhep.2013.02.012. Epub 2013 Feb 26.

73. TuomilehtoJ., Lindström J., Eriksson J., et al., for the Finnish Diabetes Prevention Study Group. Prevention of Type 2 Diabetes Mellitus by Changes in Lifestyle among Subjects with Impaired Glucose Tolerance. N Engl J Med 2001; 344:1343–1350. DOI: 10.1056/NEJM200105033441801.

74. Nadtochiy S.M., Redman E.K. Mediterranean diet and cardioprotection: the role of nitrite, polyunsaturated fatty acids and polyphenols. Nutrition (Burbank, Los Angeles County, Calif). 2011;27(7–8):733–744. doi:10.1016/j.nut.2010.12.006.

75. Simopoulos A.P. Human requirement for Q-3 polyunsaturated fatty acids. Poult Sei. 2000 Jul; 79(7):961-70.

76. Weber P.C., Leaf A. Cardiovascular effects of omega-3 fatty acids. Atherosclerosis risk factor modification, 1991.

77. Rodriguez-Leyva D., et al. The cardiovascular effects of flaxseed and its omega-3 fatty acid, alpha-linolenic acid. Can J Cardiol. 2010 November; 26(9): 489–496.

78. Leyva D.R., Zahradka P., Ramjiawan B., et al. The effect of dietary flaxseed on improving symptoms of cardiovascular disease in patients with peripheral artery disease: rationale and design of the FLAX-PAD randomized controlled trial. Contemp Clin Trials. 2011; 32: 724–730.

79. Parker H.M., Johnson N.A., Burdon C.A., et al. Omega-3 supplementation and non-alcoholic fatty liver disease: a systematic review and meta-analysis. J Hepatol. 2012 Apr;56(4):944-51. doi: 10.1016/j.jhep.2011.08.018.

80. Sonne D.P., Knop F.K. Cardiovascular effects of alpha-linolenic acid-a possible role of glucagon-like peptide-1. Exp Biol Med (Maywood). 2013 Oct;238(10):1116-7. doi: 10.1177/1535370213503434.

81. Gundermann K.-J., Gundermann S., Drozdzik M., Mohan Prasad V. Essential phospholipids in fatty liver: a scientific update. Clinical and Experimental Gastroenterology. 2016;9:105–117. doi:10.2147/CEG.S96362.

82. Kidd P.M. Cell membranes, endothelia, and atherosclerosis — the importance of Phosphatidylcholine. Altern Med Rev 1996;1:148–167.

83. Un C., Zheng X., Tan Z. et al. Clinical Observation on Polyene Phosphatidyl Choline and Metformin in the Treatment of Type 2 Diabetes and Non-alcoholic Fatty Liver Disease // Clin Focus. — 2008. — Vol. 23, N 17. — P. 1272–3.

84. Yin Kong. Observation for curative effect of Essentiale in treatment of fatty liver caused by diabetes mellitus // Med J Qilu. — 2000. — Vol. 15. — P. 277–8.

85. Guo S. Observation on treatment of fatty liver disease with polyene phosphatidylcholine // China Foreign Med J. 2007. Vol. 5, Issue 10.

86. Kuntz E., Kuntz H.-D. Гепатология: учебное пособие и атлас. 3-е изд. — Springer Press, Heidelberg 2008; глава 40., С. 896.

87. Sas et al. Beneficial influence of polyunsaturated Phosphatidylcholine enhances functional liver condition and liver structure in patients with Nonalcoholic steatohepatitis Journal of Hepatology 2013; 58: S549 (EASL congress 2013) & Hepatol Int (2013) 7 (Suppl 1):S71.

88. Singal A.K., Jampana S.C., Weinman S.A. Liver Int. 2011; 31(10): 1432–1448.

89. OkiyamaW. et al. J Hepatol. 2009 Jun; 50(6): 1236–1246.

90. MazzellaN., Ricciardi L.M., Mazzotti A., Marchesini G. The role of medications for the management of patients with NAFLD. Clin Liver Dis. 2014 Feb;18(l):73–89. doi: 10.1016/j. cld.2013.09.005.

91. Hallsworth K., Avery L., Trenell M.I. Targeting Lifestyle Behavior Change in Adults with NAFLD During a 20-min Consultation: Summary of the Dietary and Exercise Literature. Curr Gastroenterol Rep. 2016 Mar;18(3):ll. doi: 10.1007/S11894-016-0485-1.

1 ... 10 11 12 13 14 15 16 17 18 19
Перейти на страницу:

Комментарии
Минимальная длина комментария - 25 символов.
Комментариев еще нет. Будьте первым.
Правообладателям Политика конфиденциальности